Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Sonoda, Shozo ^a   Sakamoto, Taiji ^a   Otsuka, Hiroki ^a   Yoshinaga, Narimasa ^a   Yamashita, Toshifumi ^a   Ki I, Yuya ^a   Okubo, Akiko ^a   Yamashita, Takehiro ^a   Arimura, Noboru ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

AMD; Drug; Enhanced depth imaging optical coherence tomography interventional immunology; Ranibizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; RANIBIZUMAB;

AGED; ARTICLE; CAPILLARY PERMEABILITY; CHOROID; CHOROID DISEASE; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; VASCULARIZATION; VERY ELDERLY; VISUAL ACUITY; CHOROID DISEASES;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CAPILLARY PERMEABILITY; CHOROID; CHOROID DISEASES; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; VISUAL ACUITY;

EID: 84883585688     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-43     Document Type: Article

References (40)

1. Polypoidal choroidal vasculopathy: a review. Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA, Surv Ophthalmol 2010 55 501 515 10.1016/j. survophthal.2010.03.004 20850857
2. Pulsatile blood flow in the polypoidal choroidal vasculopathy. Okubo A, Ito M, Sameshima M, Uemura A, Sakamoto T, Ophthalmology 2005 112 1436 1441 10.1016/j.ophtha.2005.03.017 15996735 (Pubitemid 41074636)
3. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Maruko I, Iida T, Saito M, Nagayama D, Saito K, Am J Ophthalmol 2007 144 15 22 10.1016/j.ajo.2007.03.047 17509509 (Pubitemid 46963198)
4. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Sasahara M, Tsujikawa A, Musashi K, Gotoh N, Otani A, Mandai M, Yoshimura N, Am J Ophthalmol 2006 142 601 607 10.1016/j.ajo.2006.05.051 17011852 (Pubitemid 44442072)
5. Clinical features of early and late stage polypoidal choroidal vasculopathy characterized by lesion size and disease duration. Okubo A, Hirakawa M, Ito M, Sameshima M, Sakamoto T, Graefes Arch Clin Exp Ophthalmol 2008 246 491 499 10.1007/s00417-007-0680-8 17917739 (Pubitemid 351447961)
6. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, Wong TY, Aung T, Prog Retina Eye Res 2010 29 19 29 10.1016/j.preteyeres.2009.10.001
7. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y, Ophthalmology 2008 115 141 146 10.1016/j.ophtha.2007.02.031 17582498 (Pubitemid 350309415)
8. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Cho M, Barbazetto IA, Freund KB, Am J Ophthalmol 2009 148 70 78 e1 10.1016/j.ajo.2009.02.012 19403115
9. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Yoshida Y, Kohno T, Yamamoto M, Yoneda T, Iwami H, Shiraki K, Jpn J Ophthalmol 2013 57 283 293 10.1007/s10384-013-0234-z 23413039
10. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, Yoshimura N, Retina 2007 27 335 341 10.1097/01.iae.0000233647.78726.46 17460589 (Pubitemid 46398898)
11. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Matsumiya W, Honda S, Bessho H, Kusuhara S, Tsukahara Y, Negi A, J Ophthalmic 2011 2011 742020
12. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, Hanutsaha P, Pokawattana N, Br J Ophthalmol 2010 94 1045 1051 10.1136/bjo.2009.173120 20530656
13. Enhanced depth imaging spectral-domain optical coherence tomography. Spaide RF, Koizumi H, Pozzoni MC, Am J Ophthalmol 2008 146 496 500 10.1016/j.ajo.2008.05.032 18639219
14. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Spaide RF, Am J Ophthalmol 2009 147 644 652 10.1016/j.ajo.2008.10.005 19152869
15. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Jirarattanasopa P, Ooto S, Nakata I, Tsujikawa A, Yamashiro K, Oishi A, Yoshimura N, Invest Ophthalmol Vis Sci 2012 53 3663 3672 10.1167/iovs.12-9619 22570352
16. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T, Am J Ophthalmol 2011 151 594 603 10.1016/j.ajo.2010.10.030 21295766
17. Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Manjunath V, Goren J, Fujimoto JG, Dukers JS, Am J Ophthalmol 2011 152 663 668 10.1016/j.ajo.2011.03.008 21708378
18. If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine. Ehrenstein MR, Mauri C, J Exp Med 2011 204 2249 2252 (Pubitemid 47529311)
19. Cytokines and interventional immunology. Hafler DA, Nat Rev Immunol 2077 7 423 442
20. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Arimura N, Otsuka H, Yamakiri K, Duker JS, Ophthalmology 2009 116 921 926 10.1016/j.ophtha.2008.12. 024 19410951
21. Repeatability and reproducibility of subfoveal choroidal thickness in normal eyes of Japanese using different SD-OCT devices. Yamashita T, Yamashita T, Shirasawa M, Arimura N, Terasaki H, Sakamoto T, Invest Ophthalmol Vis Sci 2012 53 1102 1107 10.1167/iovs.11-8836 22247474
22. The measurement of observer agreement for categorical data. Landis JR, KochG G, Biometrics 1977 33 159 174 10.2307/2529310 843571 (Pubitemid 8054849)
23. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Lim JW, Kim MU, Graefes Arch Clin Exp Ophthalmol 2011 249 969 974 10.1007/s00417-010-1581-9 21140161
24. Digital indocyanine green videoangiography of central serous chorioretinopathy. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Hope-Ross M, Orlock DR, Arch Ophthalmol 1994 112 1057 1062 10.1001/archopht.1994. 01090200063023 8053819 (Pubitemid 24272611)
25. Central serous chorioretinopathy and indocyanine green angiography. Piccolino FC, Borgia L, Retina 1994 14 231 242 10.1097/00006982-199414030-00008 7973118 (Pubitemid 24308054)
26. Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K, Nishimura T, Retina 1999 19 12 21 10.1097/00006982-199901000-00003 10048368 (Pubitemid 30387535)
27. Central serous chorioretinopathy: update on pathophysiology and treatment. Nicholson B, Noble J, Forooghian F, Meyerle C, Surv Ophthalmol 2013 58 103 126 10.1016/j.survophthal.2012.07.004 23410821
28. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK, Br J Ophthalmol 2003 87 1453 1458 10.1136/bjo.87.12.1453 14660450 (Pubitemid 38010546)
29. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H, Am J Ophthalmol 2011 152 784 792 e2 10.1016/j.ajo.2011.04.008 21742303
30. Relationship Between Clinical Characteristics of Polypoidal Choroidal Vasculopathy and Choroidal Vascular Hyperpermeability. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S, Am J Ophthalmol 2013 155 305 313 10.1016/j.ajo.2012.07. 018 23022162
31. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Fujiwara T, Imamura Y, Margolis R, Slakter JS, Spaide RF, Am J Ophthalmol 2009 148 445 450 10.1016/j.ajo.2009.04.029 19541286
32. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK, Ophthalmology 2011 118 111 118 10.1016/j.ophtha.2010.04.016 20678799
33. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Lai TY, Lee GK, Luk FO, Lam DS, Retina 2001 31 1581 1588
34. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Sato T, Kishi S, Matsumoto H, Mukai R, Am J of Ophthalmol 2013 156 95 105 e101 10.1016/j.ajo.2013.02.006
35. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Saito M, Iida T, Kano M, Itagaki K, Graefes Arch Clin Exp Ophthalmol 2013 PMID: 23553286
36. Association of elastin gene polymorphism to age-related macular degeneration and polypoidal choroidal vasculopathy. Yamashiro K, Mori K, Nakata I, Tsuchihashi T, Horie-Inoue K, Nakanishi H, Tsujikawa A, Saito M, Iida T, Yamada R, Matsuda F, Inoue S, Awata T, Yoneya S, Yoshimura N, Invest Ophthalmol Vis Sci 2011 52 8780 8784 10.1167/iovs.11-8205 22003121
37. The association of CD36 variants with polypoidal choroidal vasculopathy compared to typical neovascular age-related macular degeneration. Bessho H, Honda S, Kondo N, Kusuhara S, Tsukahara Y, Negi A, Mol Vis 2012 18 121 127 22275803
38. Associations of complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes with subtypes of polypoidal choroidal vasculopathy. Tanaka K, Nakayama T, Mori R, Sato N, Kawamura A, Mizutani Y, Yuzawa M, Invest Ophthalmol Vis Sci 2011 52 7441 7444 10.1167/iovs.11-7546 21896867
39. Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings. Khan S, Engelbert M, Imamura Y, Freund KB, Retina 2012 32 1057 1068 10.1097/IAE.0b013e31823beb14 22127224
40. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Roskoski RJ, Crit Rev Oncol Hematol 2007 62 179 213 10.1016/j.critrevonc.2007. 01.006 17324579 (Pubitemid 46679285)